261 related articles for article (PubMed ID: 31738425)
1. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
Bielack SS; Cox MC; Nathrath M; Apel K; Blattmann C; Holl T; Jenewein R; Klenk U; Klothaki P; Müller-Abt P; Ortega-Lawerenz S; Reynolds M; Scheer M; Simon-Klingenstein K; Stegmaier S; Tupper R; Vokuhl C; von Kalle T
Ann Oncol; 2019 Nov; 30(Suppl_8):viii31-viii35. PubMed ID: 31738425
[TBL] [Abstract][Full Text] [Related]
2. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
Bielack SS; Cox MC; Nathrath M; Apel K; Blattmann C; Holl T; Jenewein R; Klenk U; Klothaki P; Müller-Abt P; Ortega-Lawerenz S; Reynolds M; Scheer M; Simon-Klingenstein K; Stegmaier S; Tupper R; Vokuhl C; von Kalle T
Ann Oncol; 2019 Nov; 30 Suppl 8():viii31-viii35. PubMed ID: 32223937
[TBL] [Abstract][Full Text] [Related]
3. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
4. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
[TBL] [Abstract][Full Text] [Related]
5. Treatment of infantile fibrosarcoma associated to an abdominal aortic aneurysm with larotrectinib: a case report.
Corral Sánchez MD; Galán Gómez V; Sastre Urgelles A; Plaza López de Sabando D; Rubio Aparicio P; Martínez Martínez L; Alonso Gamarra E; Pozo Kreilinger JJ; Regojo Zapata RM; López Gutiérrez JC; Antolín Alvarado E; Gómez Martín F; Sánchez Torres AM; Marín Manzano E; González Del Valle L; Pérez-Martínez A
Pediatr Hematol Oncol; 2021 Aug; 38(5):504-509. PubMed ID: 33622165
[TBL] [Abstract][Full Text] [Related]
6. Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Nagasubramanian R; Wei J; Gordon P; Rastatter JC; Cox MC; Pappo A
Pediatr Blood Cancer; 2016 Aug; 63(8):1468-70. PubMed ID: 27093299
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.
Ziegler DS; Wong M; Mayoh C; Kumar A; Tsoli M; Mould E; Tyrrell V; Khuong-Quang DA; Pinese M; Gayevskiy V; Cohn RJ; Lau LMS; Reynolds M; Cox MC; Gifford A; Rodriguez M; Cowley MJ; Ekert PG; Marshall GM; Haber M
Br J Cancer; 2018 Sep; 119(6):693-696. PubMed ID: 30220707
[TBL] [Abstract][Full Text] [Related]
8. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
Caldwell KJ; De La Cuesta E; Morin C; Pappo A; Helmig S
Pediatr Blood Cancer; 2020 Sep; 67(9):e28330. PubMed ID: 32452122
[TBL] [Abstract][Full Text] [Related]
9. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.
O'Reilly EM; Hechtman JF
Ann Oncol; 2019 Nov; 30(Suppl_8):viii36-viii40. PubMed ID: 31605106
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic strategies and clinical evolution of patients with infantile fibrosarcoma: a unique paediatric case series.
Corral Sánchez MD; Jiménez Carrascoso R; Rubio Aparicio P; Plaza López de Sabando D; Sastre Urgelles A; Pozo-Kreilinger JJ; López Gutiérrez JC; Gómez Cervantes M; Ortiz Cruz EJ; Pérez-Martínez A
Clin Transl Oncol; 2023 Nov; 25(11):3307-3311. PubMed ID: 37097530
[TBL] [Abstract][Full Text] [Related]
11. Limb salvage of an infant with infantile fibrosarcoma using TRK inhibitor larotrectinib.
Sahni S; Rastogi S; Yadav R; Barwad A
Ecancermedicalscience; 2023; 17():1575. PubMed ID: 37533946
[TBL] [Abstract][Full Text] [Related]
12. An infant with ETV6-NTRK3 fusion-positive congenital infantile fibrosarcoma and delayed response to conventional chemotherapy avoiding the need for TRK inhibition.
Vedi A; Holland K; Cross J; Muthusamy B; Behjati S; Hook CE; Murray MJ
Pediatr Blood Cancer; 2020 Oct; 67(10):e28628. PubMed ID: 32748441
[No Abstract] [Full Text] [Related]
13. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
[TBL] [Abstract][Full Text] [Related]
14. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
15. RAF1 gene fusions are recurrent driver events in infantile fibrosarcoma-like mesenchymal tumors.
Motta M; Barresi S; Pizzi S; Bifano D; Lopez Marti J; Garrido-Pontnou M; Flex E; Bruselles A; Giovannoni I; Rotundo G; Fragale A; Tirelli V; Vallese S; Ciolfi A; Bisogno G; Alaggio R; Tartaglia M
J Pathol; 2024 Jun; 263(2):166-177. PubMed ID: 38629245
[TBL] [Abstract][Full Text] [Related]
16. Infantile fibrosarcoma-like tumor driven by novel
Gupta A; Belsky JA; Schieffer KM; Leraas K; Varga E; McGrath SD; Koo SC; Magrini V; Wilson RK; White P; Mardis ER; Jatana KR; Cottrell CE; Setty BA
Cold Spring Harb Mol Case Stud; 2020 Oct; 6(5):. PubMed ID: 33028644
[TBL] [Abstract][Full Text] [Related]
17. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.
Church AJ; Calicchio ML; Nardi V; Skalova A; Pinto A; Dillon DA; Gomez-Fernandez CR; Manoj N; Haimes JD; Stahl JA; Dela Cruz FS; Tannenbaum-Dvir S; Glade-Bender JL; Kung AL; DuBois SG; Kozakewich HP; Janeway KA; Perez-Atayde AR; Harris MH
Mod Pathol; 2018 Mar; 31(3):463-473. PubMed ID: 29099503
[TBL] [Abstract][Full Text] [Related]
18. Second Report of
Hughes CE; Correa H; Benedetti DJ; Smith B; Sumegi J; Bridge J
Pediatr Dev Pathol; 2021; 24(6):554-558. PubMed ID: 34120511
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors.
Kang J; Park JW; Won JK; Bae JM; Koh J; Yim J; Yun H; Kim SK; Choi JY; Kang HJ; Kim WS; Shin JH; Park SH
Diagn Pathol; 2020 Sep; 15(1):114. PubMed ID: 32957984
[TBL] [Abstract][Full Text] [Related]
20. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
Mortensen L; Ordulu Z; Dagogo-Jack I; Bossuyt V; Winters L; Taghian A; Smith BL; Ellisen LW; Kiedrowski LA; Lennerz JK; Bardia A; Spring LM
Oncologist; 2021 Oct; 26(10):818-824. PubMed ID: 34176200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]